(:BCR)
Business Focus: N/A
Dec 29, 2017 09:48 am ET
BD Completes Bard Acquisition, Creating New Global Health Care Leader
FRANKLIN LAKES, N.J., Dec. 29, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has completed the acquisition of C. R. Bard, Inc. (NYSE: BCR), creating a new health care industry leader with approximately $16 billion in annualized revenue.
Dec 28, 2017 05:40 pm ET
Huntington Ingalls Industries Set to Join S&P 500; Scientific Games to Join S&P MidCap 400 and Ultra Clean Holdings to Join S&P SmallCap 600
NEW YORK, Dec. 28, 2017 /PRNewswire/ -- S&P MidCap 400 constituent Huntington Ingalls Industries Inc. (NYSE: HII) will replace C. R. Bard Inc. (NYSE: BCR) in the S&P 500, S&P SmallCap 600 constituent Scientific Games Corp. (NASD: SGMS) will replace Huntington Ingalls Industries in the S&P MidCap 400, and Ultra Clean Holdings Inc. (NASD: UCTT) will replace Scientific Games in the S&P SmallCap 600 effective prior to the open of trading on Wednesday, January 3, 2018. S&P 500 constituent Becton, Dickinson and Co. (NYSE: BDX) is acquiring C.R. Bard in a deal expected to be
Dec 28, 2017 05:54 am ET
BD Statement On MOFCOM Clearance Of Bard Acquisition
FRANKLIN LAKES, N.J., Dec. 28, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, issued the following statement regarding today's clearance by the Ministry of Commerce of the People's Republic of China (MOFCOM) for BD to acquire C. R. Bard (NYSE: BCR), contingent on BD divesting its soft tissue core needle biopsy product line:
Dec 22, 2017 01:36 pm ET
BD Statement On FTC Clearance Of Bard Acquisition
FRANKLIN LAKES, N.J., Dec. 22, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, issued the following statement regarding today's clearance by the U.S. Federal Trade Commission (FTC) for BD to acquire C. R. Bard (NYSE: BCR), contingent on the divestitures of BD's soft tissue core needle biopsy product line and C. R. Bard's Aspira® product line of tunneled home drainage catheters and accessories:
Nov 29, 2017 07:50 am ET
Market Trends Toward New Normal in Cloudera, C.R. Bard, Jabil Circuit, Valero Energy, Navient, and Interpace Diagnostics Group — Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, Nov. 29, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cloudera, Inc. (NYSE:CLDR), C.R. Bard, Inc....
Nov 16, 2017 06:36 am ET
BD Statement On Merit Medical Agreement To Purchase BD, Bard Product Lines
FRANKLIN LAKES, N.J., Nov. 16, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, issued the following statement regarding today's announcement by Merit Medical Systems, Inc. that it has signed a definitive agreement to acquire BD's soft tissue core needle biopsy product line and C. R. Bard's (NYSE: BCR) Aspira® product line of tunneled home drainage catheters and accessories, contingent on the completion of the BD acquisition of Bard:
Oct 25, 2017 04:15 pm ET
Bard Announces Third Quarter Results
C. R. Bard, Inc. (NYSE: BCR) today reported 2017 third quarter financial
results. The company has included supplemental financial data on its
website related to this earnings release. Third quarter 2017 net sales
were $989.8 million, an increase of 5 percent over the prior-year period
on an as-reported basis. Excluding the impact of foreign exchange, third
quarter 2017 net sales also increased 5 percent over the prior-year
period.
Oct 18, 2017 11:17 am ET
BD Statement On European Commission Conditional Clearance Of Bard Acquisition
FRANKLIN LAKES, N.J., Oct. 18, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, issued the following statement regarding today's clearance by the European Commission for BD to acquire C.R. Bard (NYSE: BCR), contingent on BD divesting its soft tissue core needle biopsy product line:
Oct 11, 2017 04:15 pm ET
Bard Declares Quarterly Dividend
The Board of Directors of C. R. Bard, Inc. (NYSE-BCR) today declared a
regular quarterly dividend of 26 cents per share on Bard's common stock.
In connection with the pending merger with Becton, Dickinson & Company,
the quarterly dividend will be payable on December 29, 2017 to
shareholders of record at the close of business on December 8, 2017.
Aug 08, 2017 05:54 pm ET
Bard Shareholders Approve Proposed Merger With Becton, Dickinson
MURRAY HILL, N.J. and FRANKLIN LAKES, N.J., Aug. 8, 2017 /PRNewswire/ -- C. R. Bard, Inc. (NYSE: BCR) ("Bard") and Becton, Dickinson and Company (NYSE: BDX) ("BD") today announced the results of Bard's special meeting of shareholders, held on August 8, 2017 and at which a quorum was present, for Bard shareholders to consider and vote upon the proposed merger of Bard with BD. Bard shareholders approved the definitive merger agreement, with approximately 99% of shares voting cast in favor of the proposal.
Jun 09, 2017 06:15 pm ET
BD and Bard Receive Second Requests from FTC under HSR Act
FRANKLIN LAKES, N.J., and MURRAY HILL, N.J., June 9, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and C. R. Bard, Inc. (NYSE: BCR), a medical technology leader in the fields of vascular, urology, oncology and surgical specialty products, announced today that the two companies have each received a request for additional information ("second request") from the Federal Trade Commission (FTC) in connection with BD's pending acquisition of Bard. The second request was issued under notification requirements of the Hart-Scott-Rodi
May 15, 2017 07:48 pm ET
Apr 27, 2017 05:39 pm ET
INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of C. R. Bard, Inc. to Becton, Dickinson and Company for $317 Per Share is Fair to Shareholders - BCR
NEW YORK, April 27, 2017 /PRNewswire/ -- The following statement is being issued by Levi & Korsinsky, LLP:
Apr 25, 2017 01:54 pm ET
WeissLaw LLP: The C. R. Bard, Inc. and Becton, Dickson and Company Merger May Not Be in the Best Interests of BCR Unitholders
NEW YORK, April 25, 2017 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of C. R. Bard, Inc. ("BCR" or the "Company")(NYSE: BCR) in connection with the proposed merger of the Company with Becton, Dickson and Company ("BDX")(NYSE: BDX). Under the terms of the agreement, the Company's shareholders will receive $222.93 in cash and 0.5077 of a share of BDX for each share of BCR they own, representing consideration of $317.00 based on BDX's April 21 closing price.
Apr 25, 2017 10:41 am ET
C.R. BARD INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of C.R. Bard, Inc.
NEW ORLEANS, April 24, 2017 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of C.R. Bard, Inc. ("Bard" or the "Company") (NYSE: BCR) to Becton, Dickinson and Company (NYSE: BDX). Under the terms of the proposed transaction, shareholders of Bard will receive only $317.00 in cash for each share of Bard that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Apr 24, 2017 05:07 pm ET
Harwood Feffer LLP Announces Investigation of C. R. Bard, Inc.
NEW YORK, April 24, 2017 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of C. R. Bard, Inc. ("Bard" or the "Company") (NYSE: BCR) concerning the proposed acquisition of the Company by Becton, Dickinson and Company ("BD").
Apr 23, 2017 10:23 pm ET
Act Now - Shareholder Alert: Monteverde & Associates PC Announces An Investigation Of C.R. Bard, Inc. - BCR
NEW YORK, April 23, 2017 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a boutique securities class action firm headquartered at the Empire State Building in New York City, is investigating C.R. Bard, Inc. ("Bard" or the "Company") (NYSE: BCR) and its Board of Directors for potential breaches of fiduciary duties in connection with the sale of the Company to Becton, Dickinson and Company ("BD") (NYSE: BDX). The Company's stockholders will only receive $222.93 in cash and 0.5077 shares of BD stock for each Bard share they own.
Apr 23, 2017 06:05 pm ET
BD Announces Appointment Of Tom Polen As President
FRANKLIN LAKES, N.J., April 23, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today the appointment of Tom Polen, 43, as president of BD, effective immediately. In his new role, Mr. Polen will oversee all of BD's operating segments – the Medical and Life Sciences segments, as well as the new Interventional segment, which will include the C. R. Bard, Inc. (NYSE: BCR) businesses following the close of BD's acquisition of Bard, which was also announced today. Mr. Polen, currently executive vice president and president
Apr 23, 2017 06:04 pm ET
BD To Acquire Bard For $24 Billion
FRANKLIN LAKES, N.J. and MURRAY HILL, N.J., April 23, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and C. R. Bard, Inc. (NYSE: BCR), a medical technology leader in the fields of vascular, urology, oncology and surgical specialty products, announced today a definitive agreement under which BD will acquire Bard for $317.00 per Bard common share in cash and stock, for a total consideration of $24 billion. The agreement has been unanimously approved by the Boards of Directors of both companies.
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.